Sleeping less than six hours a night may increase cardiovascular risk

People who sleep less than six hours a night may be at increased risk of cardiovascular disease compared with those who sleep between seven and eight hours, suggests a new study published in the Journal of the American College of Cardiology. Poor quality sleep increases the risk of atherosclerosis - plaque buildup in the arteries throughout the body - according to the study.

"Cardiovascular disease is a major global problem, and we are preventing and treating it using several approaches, including pharmaceuticals, physical activity and diet. But this study emphasizes we have to include sleep as one of the weapons we use to fight heart disease--a factor we are compromising every day," said senior study author José M. Ordovás, PhD, researcher at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid and director of nutrition and genomics at the Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University. "This is the first study to show that objectively measured sleep is independently associated with atherosclerosis throughout the body, not just in the heart."

Previous studies have shown that lack of sleep raises the risk of cardiovascular disease by increasing heart disease risk factors such as glucose levels, blood pressure, inflammation and obesity, he said.

The new study included 3,974 bank employees in Spain from the PESA CNIC- Santander Study, led by JACC editor-in-chief Valentin Fuster, MD, PhD, which uses imaging techniques to detect the prevalence and rate of progression of subclinical vascular lesions in a population with an average age of 46 years. All participants were without known heart disease and two-thirds were men. All participants wore an actigraph, a small device that continuously measures activity or movement, for seven days to measure their sleep. They were divided into four groups: those who slept less than six hours, those who slept six to seven hours, those who slept seven to eight hours and those who slept more than eight hours. The participants underwent 3D heart ultrasound and cardiac CT scans to look for heart disease.

The study found that when traditional risk factors for heart disease were considered, participants who slept less than six hours were 27 percent more likely to have atherosclerosis throughout the body compared with those who slept seven to eight hours. Similarly, those who had a poor quality of sleep were 34 percent more likely to have atherosclerosis compared with those who had a good quality of sleep. Quality of sleep was defined by how often a person woke during the night, and the frequency of movements during the sleep which reflect the sleep phases.

"It is important to realize that shorter sleep duration that is of good quality can overcome the detrimental effects of the shorter length," Fuster said.

The study also suggested sleeping more than eight hours a night may be associated with an increase in atherosclerosis. While the number of participants who slept more than eight hours was small, the study found women who slept more than eight hours a night had an increased risk of atherosclerosis.

Alcohol and caffeine consumption were higher in participants with short and disrupted sleep, the study found. "Many people think alcohol is a good inducer of sleep, but there's a rebound effect," Ordovás said. "If you drink alcohol, you may wake up after a short period of sleep and have a hard time getting back to sleep. And if you do get back to sleep, it's often a poor-quality sleep."

While some studies show drinking coffee can have positive effects on the heart, Ordovás said it can depend on how quickly a person metabolizes the coffee. "Depending on your genetics, if you metabolize coffee faster, it won't affect your sleep, but if you metabolize it slowly, caffeine can affect your sleep and increase the odds of cardiovascular disease," he said.

The new study is different from previous studies on sleep and heart health in several ways, Ordovás said. It is larger than many earlier studies and focused on a healthy population. Many previous studies have included people with sleep apnea or other health problems. While other studies have relied on questionnaires to determine how much sleep participants got, this study used actigraphs to obtain objective measures of sleep.

"What people report and what they do are often different," he said.

The study also used state-of-the-art 3D ultrasound to measure atherosclerosis throughout the body, not just in the heart.

In an editorial, Daniel J. Gottlieb, MD, MPH, and Deepak L. Bhatt, MD, MPH, from the VA Boston Healthcare System and Brigham and Women's Hospital Division of Sleep Medicine at Harvard Medical School and Brigham and Women's Hospital Heart and Vascular Center said further studies are needed to determine whether changing sleep behaviors will improve heart health.

"The potentially enormous impact of sleep deprivation and disruption on population health, reinforced by the present study, is ample justification for such trials, which are needed to place sleep with confidence alongside diet and exercise as a key pillar of a healthy lifestyle," they wrote.

Fernando Domínguez, Valentín Fuster, Juan Miguel, Fernández-Alvira, Leticia Fernández-Friera, Beatriz López-Melgar, Ruth Blanco-Rojo, Antonio Fernández-Ortiz, Pablo García-Pavía, Javier Sanz, José M Mendiguren, Borja Ibañez, Héctor Bueno, Enrique Lara-Pezzi, José M Ordovás.
Association of Sleep Duration and Quality With Subclinical Atherosclerosis.
Journal of the American College of Cardiology, Volume 73. doi: 10.1016/j.jacc.2018.10.060.

Most Popular Now

Compound that kills drug-resistant fungi is isolat…

Antimicrobial and antifungal resistance, which describe the ability of bacteria and other pathogens to resist the effects of drugs to which they were once sensitive, is a...

Novartis receives FDA approval for Mayzent® (sipon…

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple scl...

First bacterial genome created entirely with a com…

All the genome sequences of organisms known throughout the world are stored in a database belonging to the National Center for Biotechnology Information in the United Sta...

Liver, colon cancer cells thwarted by compounds de…

The plant that adds flavor, color and bitterness to beer also produces a primary compound that thwarts cancer cells, and two important derivatives of the compound do as w...

Immune cells fighting blood cancer visualized for …

When cancer escapes the immune system, our defenses are rendered powerless and are unable to fight against the disease. Chimeric antigen receptor T cells (CAR T cells) re...

Clinical trial finds therapy to be well-tolerated …

A phase I clinical trial that set out to assess the safety of a new combination therapy for a type of aggressive brain tumour has found the treatment to be well tolerated...

FDA approves treatment for patients with a type of…

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called no...

Selumetinib granted US Breakthrough Therapy Design…

AstraZeneca and MSD, Inc., Kenilworth, NJ, US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) ha...

Boehringer Ingelheim announces FDA and EMA regulat…

Boehringer Ingelheim has filed for regulatory approval of nintedanib in patients with systemic sclerosis associated interstitial lung disease (SSc-ILD) with the FDA and E...

Novartis adds clinical and preclinical anti-inflam…

Novartis announced that it is adding to its broad portfolio of immunomodulatory medicines with the planned acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC fo...

Novartis continues transformation into a leading m…

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depo...

Forxiga approved in Japan for type-1 diabetes

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T...